期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Nampt与糖尿病并发血管病变相关性的研究进展

Research progress on relationship between Nampt and diabetes-associated vascular diseases
下载PDF
导出
摘要 尼克酰胺磷酸核糖转移酶(Nampt)是生物合成烟酰胺腺嘌呤二核苷酸(NAD)的关键限速酶,Nampt通过调节NAD的生成从而调控Sirt1的活性,参与细胞的分化、增殖及凋亡等过程。该文对Nampt与糖尿病并发血管病变相关性的研究进展作一综述。 Nicotinamide phosphoribosyl transferase （Nampt） is a key limiting enzyme of nicotinamide adenine dinucleotide （ NAD） biosynthesis .Nampt adjusts the regulation of Sirt 1 activity by adjusting NAD biosynthesis and thus participates in cell differentiation , proliferation and apoptosis and other processes .In this paper the research pro-gress on relationship between Nampt and diabetes-associated vascular diseases was reviewed .
作者 胡亚军 郭慧佳 张黎明 冯乐平
机构地区 桂林医学院 桂林医学院基础医学院
出处 《中国临床新医学》 2014年第3期267-271,共5页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词 尼克酰胺磷酸核糖转移酶(Nampt) 烟酰胺腺嘌呤二核苷酸(NAD) 糖尿病 血管病变 Nicotinamide phosphoribosyl transferase （Nampt） Nicotinamide adenine dinueleotide（NAD） Diabetes Vascular disease
分类号 R58 [医药卫生—内分泌] R54 [医药卫生—心血管疾病]
  • 相关文献

参考文献47

  • 1Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin : a protein se- creted by visceral fat that mimics the effects of insulin[ J]. Science, 2005,307(5708) : 426 - 430.
  • 2Ognjanovic S, Bao S, Yamamoto SY, et al. Genomie organization of the gene coding for human pre-B-cell colony enhancing factor and ex- pression in human fetal membranes[J]. J Mol Endocrinol, 2001,26 (2): 107- 117.
  • 3Vallejo S, Romacho T, Angulo J, et al. Visfatin impairs endotheli- um-dependent relaxation in rat and human mesentefic microvessels through nicotinamide phosphoribosyltransferase activity [ J ]. PLoS One, 2011,6 ( 11 ) : e27299.
  • 4Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-ab- dominal obesity and diabetes? [ J]. Trends Mol Med, 2005, 11 (8) :344 -347.
  • 5Vanna V, Yao-Borengasser A, Rasouli N, et al. Human visfatin ex- pression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation[J]. J Clin Endoerinol Metab, 2007, 92(2) :666 - 672.
  • 6Cosfford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans [ J ]. Am J Physiol Endocrinol Metab ,2010,298 ( 1 ) : E117 - E126.
  • 7Garten A, Petzold S, Bamikol-Oettler A, et al. Nicotinamide phos- phoribosyltransferase ( NAMPT/PBEF/visfatin ) is constitutively re- leased from human hepatocytes [ J ]. Biochem Biophys Res Commun, 2010,391 ( 1 ) :376 -381.
  • 8Kukla M, Ciupinska-Kajor M, Kajor M, et al. Liver visfatin expres- sion in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery [ J ]. Pol J Pathol, 2010,61 ( 3 ) : 147 -153.
  • 9Montecuceo F, Bauer I, Braunersreuther V, et al. Inhibition of nico- tinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction [ J ]. Antioxid Redox Signal, 2013,18 ( 6 ) : 630 - 641.
  • 10Mesko B, Poliska S, Szegedi A, et al. Peripheral blood gene ex- pression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets [ J ]. BMC Med Ge- nomics, 2010,3:15.

二级参考文献13

  • 1Unger RH, Orci L. The essential role of glucagon in the pathogenesisof diabetes mellitus[ J] ,Lancet, 1975,1 (7897) :14 -16.
  • 2YangSH, Dou KF, Song WJ. Prevalence of diabetes among men andwomen in China[J].N Engl J med,2010,362(25) :2425 -2426.
  • 3Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1 -mediated neuroprotection in an animal model of pyridoxine-inducedperipheral sensory neuropathy[ J]. Exp Neurol, 2007 , 203(2) :293-301.
  • 4HareKJ. Role of GLP-1 induced glucagon suppression in type 2 dia-betes mellitus[ J] . Dan Med Bull, 2010,57 (9) :B4181.
  • 5Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon se-cretion by incretins[J]. Diabetes Obes Metab, 2011, 13( Suppll):89 -94.
  • 6LundA, Vilsboll T, Bagger JI, et al. The separate and combined im-pact of the intestinal hormones, GIP,GLP-1,and GLP-2,on gluca-gon secretion in type 2 diabetes[ J]. Am J Physiol Endocrinol Metab,2011, 300(6) :E1038 - E1046.
  • 7Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia inType 2 diabetes : implications for therapy [ J ]. Diabetes, 2010, 59(11):2697 - 2797.
  • 8HareKJ,Vilsb0ll T,Asmar M, et al. The glucagonostatic and insuli-notropic effects of glucagon-like peptide 1 contribute equally to itsglucose-lowering action[ J]. Diabetes,2010,59(7) :1765 - 1770.
  • 9Shah P,Vella A,Basu A,et al.Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2000,85(11):4053-4059.
  • 10Larsson H,Ahrén B.Islet disfunction in insulin resisitance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance[J].Diabetes Care,2000,23(5):650-657.

共引文献14

中国临床新医学
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部